FDA Dispute Resolution Process Should Be Less Structured, Merck Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA should extend the deadline to challenge inspection findings and allow feedback for further clarification after a firm submits its response, Merck's Haggard says. The agency plans to share case studies of GMP issues to prevent future disputes.